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EgyptAbstract Aim of the work: To study the clinical characteristics and disease activity of Behc¸et’s
disease (BD) in Egyptian patients from Zagazig.
Patients and methods: Thirty-eight BD patients were recruited from the Rheumatology and
Rehabilitation Department, Zagazig University Hospitals. Demographic and clinical data were col-
lected. Disease activity was assessed using Behc¸et’s Disease Current Activity Form (BDCAF).
Results: Thirty-eight BD patients were included in this study. Their ages were 31.5 ± 7.1 years
(20–44 years) and with disease duration of 6.2 ± 3.5 years (2–12 years). There were 24 males
(63.2%) and 14 females (36.8%), with male to female ratio of 1.7:1. The BDCAF was 3.8 ± 1.3
(2–7). The frequency of the clinical manifestations was oral ulcers in 84.2%, followed by genital
ulcers in 78.2%, ocular involvement in 73.7%, arthralgia in 26.3%, arthritis in 5.3% especially
of the knees and ankles, neurological in 26.3% with headache of the same frequency, blurred vision
in 13.2%, difﬁcult hearing in 15.8%, loss of balance in 18.4% and memory loss or impaired cogni-
tive function in 26.3%, pulmonary in 26.3%, gastrointestinal in 10.5% (mostly in the form of nau-
sea and vomiting), cutaneous in 10.5% (erythema nodosum and papulopustular lesions) and none
had peripheral vascular disease.
Conclusion: In Zagazig, Eastern province, Egypt, there is a male predominance in BD patients as
other areas in Egypt, regional and worldwide countries. The clinical characteristics are comparable
to other studies. However, in Zagazig the cutaneous manifestations showed the lowest recorded
frequency, thrombosis of the extremities was not reported and the patients had a moderately
controlled disease activity.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Behc¸et’s disease (BD) bears the name of a Turkish dermatolo-
gist, Hulusi Behc¸et, who ﬁrst described the disease in 1937 [1].
It is a chronic relapsing multisystem disease of unknown
Table 1 Demographic features of Behc¸et’s disease patients.
Behc¸et’s disease patients (n= 38)
Gender N (%)
Male 24 (63.2)
Female 14 (36.8)
Male: Female 1.7:1
Mean ± SD (range)
Age (year) at the study 31.5 ± 7.1 (20–44)
Disease duration (years) 6.2 ± 3.5 (2–12)
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genesis of BD such as cytokine overproduction [2,3], oxidative
stress [4] and apoptosis [5]. Although BD occurs worldwide, it
is particularly common in countries that line the ancient Silk
Road, including Turkey which has the highest prevalence
(80–370 cases/100,000), followed by Asian and Middle Eastern
countries including Palestine, Saudi Arabia and Iran [6].
The main features of BD are recurrent aphthous stomatitis
(RAS), genital ulcerations, and ocular disease [5], as well as
mucocutaneous, articular, neurological [7], urogenital, vascu-
lar [8], intestinal [6] and pulmonary manifestations [9]. Behc¸et’s
disease is a unique clinical entity; its presentation is heteroge-
nous in different areas of the world. Central nervous system
involvement is more prevalent in patients of northern Europe
and the United States of America and gastrointestinal manifes-
tations are more common in Japanese cases [10]. The rate
of progression, frequencies of different manifestations and
HLA-B51 association also show geographic variation. Patients
from Mediterranean countries and Japan have more acute
courses and stronger association with HLA-B51 [11].
Measurement of disease activity in BD is essential for clinical
management and testing the efﬁcacy of treatments. It is impor-
tant to differentiate potentially reversible activity from perma-
nent damage. Added to this is the need to pool patient
information across countries to perform comparisons, particu-
larly in the case of international clinical trials. Behc¸et’s Disease
Current Activity Form (BDCAF) was developed with this in
mind on behalf of the International Scientiﬁc Committee on
Behc¸et’s Disease [12]. A higher disease activity was found in
the United States compared to Turkey. Referral patterns, age,
sex, ethnicity, and country of origin may be important in these
differences to raise the question of whether pathogenic mecha-
nisms also differ [13].
The aim of the present study was to study the clinical char-
acteristics and disease activity of Behc¸et’s disease (BD) in
Egyptian patients from Zagazig, Eastern province, Egypt.
2. Patients and methods
2.1. Study design
The design of this study was a quantitative, cross-sectional,
and descriptive one. This design was chosen because it is a use-
ful and less expensive design that enables the researchers to
meet the study objectives in a short time.
2.2. Back ground population
The target population consists of 38 patients with BD, who are
currently attending the follow-up unit of Rheumatology and
Rehabilitation Department of Zagazig University Hospitals;
which is the biggest health care center in Sharkia Governorate
in Egypt. Sharkia Governorate is located in east of Egypt and
it comprises 19 districts. According to national agency for
mobilization and statistics, it has a population of 8,566,465
inhabitants at the end of 2010.
2.3. Recruitment
Thirty-eight patients with Behc¸et’s disease were included in
this study and all were between ages of 20 and 44 years withmean ± SD of 31.5 ± 7.1 years. They were diagnosed accord-
ing to the International Study Group for Behc¸et’s disease
criteria [12]. All were recruited from the follow-up unit of
the Rheumatology and Rehabilitation Department of Zagazig
University Hospitals. Clinical data were collected from
patients during their physical routine examination and from
their medical records in the follow-up unit of the Rheumatol-
ogy and Rehabilitation Department of Zagazig University
Hospitals by qualiﬁed rheumatologist, over one year period
from November 2013 to October 2014. All demographic and
clinical data were collected and entered into a standardized
data abstraction form. All participated patients were given full
detailed written information about the study. The patients’
written consent was obtained according to the declaration of
Helsinki, and the study was approved by the local ethics
committee prior to their inclusion in the study.
2.4. Disease activity
Disease activity was assessed using Behc¸et’s Disease Current
Activity Form (BDCAF) [14].
Statistical analysis: The results for the continuous variables
are expressed as the mean, range, and standard deviation (SD).
Categorical variables are reported as the numbers of cases and
percentages. The analyses were performed using the SPSS for
Windows version 15 (SPSS Inc, Chicago, IL, USA).
3. Results
Thirty-eight patients with BD were included in this study.
Table 1 shows the demographic characteristics of patients
showing the male preponderance with male to female ratio
of 1.7:1. The frequency of the most common clinical manifes-
tations affecting BD patients and the disease activity score
(BDCAF) are presented in Table 2. The most common
affected joints were the knees and ankles. The reduction of
visual acuity is the result of uveitis, retinal vasculitis and their
complications, such as macular edema, cataract and glaucoma.
Treatment of BD in the present study was directed toward
suppression of inﬂammation and prevention of the long term
damage of the organs involved. The choice of treatment was
dependent on severity and persistence of active disease; Colchi-
cine and topical treatment were effective for mucocutaneous
manifestation. Systemic corticosteroids and/or immunosup-
pressive agents, including azathioprine, methotrexate and
cyclophosphamide, were used when the eye, brain, and
gastrointestinal tract were severely involved and genital ulcer-
ations were large, deep and severely painful. Non-steroidal
anti-inﬂammatory drugs were also an effective alternative
Table 2 Frequency of clinical manifestations and disease activity of Behc¸et’s disease patients.
Manifestations N (%)
Behc¸et’s disease patients (n = 38)
Muco-cutaneous
Oral ulcers 32 (84.2)
Genital ulcers 30 (78.2)
Cutaneous
Erythema nodosum 4 (10.5)
Papulo-pustular lesions 2 (5.3)
Musculoskeletal
Arthralgia 10 (26.3)
Arthritis 2 (5.3)
Gastrointestinal
Nausea and vomiting 4 (10.5)
Diarrhea 0 (0.0)
Ocular
Diminution of vision 28 (73.7)
Ant. Segment involvement 20 (51.3)
Post. Segment involvement 16 (41)
Ant. & Post. Segments involvement (mixed) 8 (20.5)
Neurological
Headache 10 (26.3)
Central nervous system involvement
Black out 0 (0)
Diﬃcult speech 0 (0)
Blurred vision 5 (13.2)
Diﬃcult hearing 6 (15.8)
Loss of balance 7 (18.4)
Memory loss and/ or impaired cognitive functions 10 (26.3)
Peripheral nervous system
Weakness or diminished sensation of face 2 (5.3)
Weakness or diminished sensation of arm 3 (7.8)
Weakness or diminished sensation of leg 6 (15.8)
Pulmonary
Chest pain 10 (26.3)
Breathlessness 2 (5.3)
Coughed up blood 2 (5.3)
Peripheral vascular involvement
Pain/swelling/discoloration of the face, arm or legs 0 0
Behc¸et’s Disease Current Activity Form (BDCAF)
Mean ± SD (range) 3.8 ± 1.3 (2–7)
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lesion. At the same time, inﬂiximab was used for severe
active cases of uveitis and/or neurological manifestations
that resisted to combination of high dose steroids and
immunosuppressors. These treatments seemed to be effective
without obvious side-effects during follow-up.
4. Discussion
To our knowledge, no previous population-based study has
systematically examined the clinical features of BD in Sharkia
Governorate, Eastern Egypt. In this study, the age of the
patients was 31.5 ± 7.1 years (range 20–44 years) and was
present more often in men (24/38, 63.2%) than in women
(14/38, 36.8%), with a male to female ratio of 1.7:1. Similarly
the study of Savey et al. [15] showed that 69.6% of patientswere male and 30.4% were female. Gender distribution in
BD patients varies widely depending on their ethnic origin
and country of residence. It seems that the genetic and envi-
ronmental factors may inﬂuence the expression of BD. The
male to female ratio was 0.98 in Japan, 0.63 in Korea, 1.19
in Iran, 1.03 in Turkey, 1.8 in India, 3.4 in Saudi Arabia, 4.9
in Kuwait, 3 in Iraq, 2.8 in Jordan, 1.3 in Lebanon, 2 in Mor-
occo, 0.64 in Palestine, 1.42 in Greece, 2.4 in Italy, and 1 in
Germany [20]. Male gender is a main factor associated with
mortality in BD and is reported to markedly inﬂuence BD
expression and course [16] and those patients tended to have
more ﬂare of BD compared to female [17]. In another study
on Egyptian BD patients, the male; female ratio was 4.8:1 [2].
In our series, clinical features of BD were signiﬁcantly dom-
inated by mucocutaneous involvement (oral and genital ulcers),
which are characterized by unpredictable exacerbations and
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patients (84.2%) and genital ulcers in 30 patients (78.2%). This
was consistent with the study of Davatchi et al. [18] who
reported that oral aphthous ulcers were seen in 96.8% of
patients in Iran, 98.2% in Japan, 100% in Turkey, 97.5% in
Korea, 100% in Morocco, and 100% in England. Genital aph-
thous ulcerations were seen less frequently; they were detected
in 65.3% in Iran, 73.2% in Japan, 88.2% in Turkey, 56.7% in
Korea, 83.5% in Morocco, and 89% in England. Similarly the
study ofMikaniki et al., [19] found that the most common clin-
ical ﬁnding among BD patients was oral aphthous ulcerations
(90%) followed by genital ulcers (60%). The prevalence of oral
and genital ulcers in our patient population is comparable to
that reported from other studies on Egyptian BD patients
where oral ulcers were present in 100% and genital ulcers in
93.3% [8] and in 100% and 82% respectively [20]. Moreover,
in Kuwait [21] oral ulcers were seen in 100% and genital ulcers
in 93%. However, in another study on Egyptian BD patients,
even though recurrent oral ulcers were similarly present
in 100% of the cases, genital ulcers were reported in only
35% [22].
In the current study 6 patients (15.8%) had cutaneous
lesions. Four of those patients (10.5%) had erythema nodosum
and 2 (5.3%) had papulopustular lesions. To our knowledge,
this is the lowest recorded frequency of cutaneous manifesta-
tions. It appears that some environmental or genetic factors
speciﬁc to our population may cause changes in the clinical
manifestations of the disease. A higher ratio of skin lesions
was reported in other studies on Egyptian BD patients
(53.1%) [5] and (86.7%) [8]. It is reported to be high also in
other Middle East countries; Saudi Arabia 57% [23], Iraq
75% [24], Iran [25] and Kuwait 76% [21]. Furthermore, in
Korea it was also higher (84.3%) [26] and in Hong Kong
where erythema nodosum was present in 74%, folliculitis in
44% and acneiform nodules in 30% [27].
Arthritis in BD is usually mono-articular or oligoarticular,
non-deforming, non-erosive, with predilection of the lower
limbs and lasting from several weeks to months [28]. Similarly,
in the present study joint manifestations were present in 12
patients (31.6%) and the most common affected joints were
knees and ankles. Arthralgia was present in 10 patients
(26.3%) and arthritis in 2 (5.3%). In agreement were the results
of Benamour et al. [29] that showed that joints were involved in
56.6% of BD patients with knees and ankles most commonly
affected. This was in agreement with the prevalence of joint
involvement among BD patients in other countries for instance;
it was 34.3% in Iran, 57% in Japan, 16% in Turkey, 24.2% in
Korea [30], while it was 54% in southern [27] and 44% in north-
ern China [31]. In regional countries, a higher frequency of joint
involvement was reported in Kuwaiti patients (76%) [21], while
the frequency was comparable in Iraqi (48%) [24] and Saudi
Arabian (37%) BD patients [23]. In other studies on Egyptian
BD patients, arthritis was present in 30.6% [5] and arthralgia
and arthritis were also reported in 12.5% each [9].
The prevalence of gastrointestinal manifestations in BD var-
ied from 1 to 60% depending on the geographic area [32]. In
our patients, gastrointestinal manifestations were in the form
of abdominal pain associated with nausea and vomiting and
it occurred in 4 BD patients (10.5%) which were comparable
to that in Lebanon (10%) [33]; and higher than that reported
in Saudi Arabia (4%) [23], Korea (4%) [34] and Iraq (3.3%)
[35]. However, a higher prevalence was reported in Singapore(40.5%) [36], China (36%) [37], Kuwait (21%) [21] and Japan
(16%) [38]. In the study of Hassan et al. [8], gastritis was also
present in 10% of the cases.
Ocular involvement is bilateral in the majority of cases,
although the severity may be asymmetrical. Characteristically,
it occurs within the ﬁrst 2–3 years of the onset of Behc¸et’s dis-
ease being the presenting feature in approximately 20% of
patients [39]. Its frequency varies from 40% to 70% among
different populations and visual loss occurs in up to 25% of
the affected patients [40]. As a chronic, relapsing bilateral uve-
itis involving both anterior and posterior chambers, it is a sig-
niﬁcant cause of morbidity. Anterior uveitis with intense
inﬂammation (hypopyon) observed in only a small fraction
of patients with eye involvement indicates a bad outcome
and is generally associated with severe retinal vasculitis. Iso-
lated anterior uveitis is infrequent and conjunctivitis is rare.
Posterior uveal inﬂammation with involvement of the retina
can be severe, causing retinal exudates, haemorrhages, venous
thrombosis, papilloedema and macular disease. Recurrent
attacks of eye disease result in structural changes, such as syn-
echiae and retinal scars. These events eventually lead to loss of
vision if left untreated [41]. In the present work ocular manifes-
tations were present in 28 BD patients (73.7%). Uveitis was
anterior in 20 patients (51.3%), posterior in 16 (41%) and pan-
uveitis occurred in 8 (20.5%). Reduction of visual acuity has
been observed in 28 patients as a result of uveitis, retinal vas-
culitis and their complications, such as macular edema, cata-
ract and glaucoma. The prevalence of eye manifestations in
our patients is more or less comparable to other studies in
Kuwait 69% [21] and Saudi Arabia 65% [23]. Lower preva-
lence was seen in Asian populations, as in Korea 50.9% [26],
Iran 55.6% [18], and southern China 35% [27]. Reasons may
be due to unknown environmental or genetic factors speciﬁc
to Asian populations. In harmony with the present results were
those of another study on 58 Egyptian BD patients where uve-
itis was present in 72.4%; anterior in 32.8%, posterior in
22.4% and both anterior/posterior in 17.2% [2].
CNS involvement occurs in 5–10% of patients and is one of
the most serious manifestations of BD causing increased mor-
bidity and mortality [42]. Most patients (80%) have parenchy-
mal brain involvement which mainly affects the brainstem,
manifested by pyramidal, followed by cerebellar and sensory
symptoms and signs, sphincter disturbances and behavioral
changes. Non-parenchymal disease (20%) takes the form of
intracranial hypertension due to dural sinus thrombosis mani-
fested by headaches and papilloedema. Simultaneous involve-
ment of the dural sinuses and brain parenchyma is unusual.
Dural sinus thrombosis has a relatively benign prognosis in
comparison with parenchymal involvement. Peripheral neu-
ropathy, which is seen frequently in other vasculitides, is very
uncommon [41]. In the present study; the frequency of neuro-
logical manifestations was 26.3% among BD patients and that
was comparable to that reported in Tunis 28.1% [43] and
Kuwait 14.0% [21]. A series of studies from a South American
country [44–46], showed similar prevalence of neurological
manifestations among BD patients (20%, 28.3% and 31.03%
respectively). A lower prevalence was reported in Turkey
(10.2%) [47], Iran (3.2%) [25], Hong Kong (5%) [27] and Sin-
gapore (5.4%) [48]. In our series; the commonest neurological
manifestations were headache and impaired cognitive func-
tions including memory loss that presented 26.3% followed
by disturbance of balance (18.4%), difﬁculties of hearing
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weakness or diminished sensation of the arm (7.8%) and
ﬁnally weakness or diminished sensation of the face (5.3%).
Blurring of vision was present in 13.2% but this could also
be attributed to the ocular involvement. In another Egyptian
study on 53 BD patients, neuro-Behc¸et was present in 39.6%
of cases with headache in 30.2% [7] and in other studies head-
ache was present in 12.5% and diminished hearing in 6.3% [9]
and headache in 30% and hearing impairment in 10% [8] of
Egyptian BD patients. Neurological involvement was also
reported in 20.4% in a study on 49 Egyptian BD patients [5].
Vascular disease is seen in up to 40% of BD patients with a
deﬁnite male preponderance. Venous involvement is more
common than arterial (75% vs 25%). Lower extremity vein
thrombosis is the most frequent manifestation of vascular
involvement followed by vena cava thrombosis, pulmonary
artery aneurysms, Budd–Chiari syndrome, peripheral artery
aneurysms and dural sinus thrombosis. Vascular involvement
in BD is usually associated with severe morbidity and
increased mortality [16]. In the current study we did not report
any case of lower or upper extremity thrombosis.
In the current study pulmonary manifestations included
chest pain (26.3%), breathlessness and coughing blood (5.3%
each) which implies pulmonary vessel involvement. In a study
on 16 Egyptian BD patients, CT angiography revealed pul-
monary artery aneurysms in nine (56.3%); pulmonary embo-
lism is 2 (12.5%), interstitial lung disease in 4 (25%),
bronchiectasis in 3 and atelectasis in another one. Hemoptysis
was reported in 62.5% and chest pain in 50% with dyspnea in
4 (25%). However, that study was conducted on a small num-
ber of patients and included CT angiography which was not an
aim of this study [9]. In the study of Hassan et al. [8], pulmon-
ary manifestations were present in 16.7% of cases while they
were present in only 6.12% in another study [5].
In the present study we used Behc¸et’s Disease Current
Activity Form (BDCAF) which is a convenient and logical
tool to describe and assess different manifestations of active
BD and thus assess the efﬁciency of therapy in controlling
the disease. In the current study, the BDCAF ranged between
2 and 7 with a mean of 3.8 ± 1.3. In other studies on Egyptian
BD patients, the disease activity as measured by BDCAF was
2.59 ± 1.52 (1–5) [2] 2.2 ± 1.5 (1–5) [8] and was higher in
another study 5.19 ± 3.2 (0–13), however in the latter study
the male: female was much higher (15:1) [4].
In conclusion, in Zagazig, Eastern province, Egypt, there is
a male predominance in BD patients as other areas in Egypt,
regional and worldwide countries. The clinical characteristics
are comparable to other studies. However, in Zagazig the cuta-
neous manifestations showed the lowest recorded frequency,
thrombosis of the extremities was not reported and the
patients had a moderately controlled disease activity. As sys-
temic major organ involvement may result in life-threatening
outcomes, an early diagnosis is recommended so that with
appropriate immunosuppressive and biological drugs the
mortality and morbidity are prevented in BD. To conﬁrm
the results of this work, further studies on a larger and
longitudinal scale are recommended.
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